Compare Ginkgo Bioworks Holdings Inc (DNA) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Kohl's Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Kohl's Corporation trades at $20.35 (market cap $2.28B). The key difference: Kohl's Corporation is far larger — about 3× Ginkgo Bioworks Holdings Inc's market cap, and Kohl's Corporation pays a 2.49% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Kohl's Corporation for 48 Days on average.
| DNA | KSS | |
|---|---|---|
Market Cap | $763.64M | $2.28B |
Volume | 3,204,177 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $24.71 |
52-Week Low | $5.48 | $11.72 |
Typical Hold Time | 7 Days | 48 Days |
Enterprise Value | $865.59M | $7.88B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
Kohl's (KSS) trades at $20.10, down 0.1% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and a new merchandising appointment signal operational improvements. Revenue trends show stabilization after several quarters of decline, with 2026 projections indicating potential margin recovery.
KSS presents a value opportunity with deep discount to sector peers, though persistent sales declines and competitive pressures remain headwinds. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism amid turnaround execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
